TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20334446

Group type: EXPERIMENTAL
Intervention: Polycap (polypill; aspirin, ramipril, simvastatin, atenolol, hydrochlorothiazide)
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Polycap
Number of subjects: 195
Study: 17610528

Group type: EXPERIMENTAL
Intervention: TMC114/r (300/100 mg bid) for 7 days
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: TMC114/r (300/100 mg bid) plus TDF (300 mg qd)
Number of subjects: 12

Group type: COMPARATOR
Intervention: TMC114/r (300/100 mg bid)
Number of subjects: 12
Study: 16139140

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (normal vasoconstrictor responses)
Number of subjects: 21
Study: 11937314

Group type: EXPERIMENTAL
Intervention: PVACE‐BOPx3 + autotransplant (Arm A)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: PVACE‐BOPx5 (Arm B)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Standard therapy with CLVPP or ABVD (not part of the trial)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: PVACE‐BOP therapy in the poorest risk group
Number of subjects: 126

Group type: COMPARATOR
Intervention: Autotransplant in first CR
Number of subjects: 126
Study: 10200005

Group type: EXPERIMENTAL
Intervention: Oral prednisone at 2 mg/kg/dose (maximum 120 mg/dose) twice daily
Number of subjects: 66

Group type: COMPARATOR
Intervention: Intravenous methylprednisolone at 1 mg/kg/dose (maximum 60 mg/dose) four times daily
Number of subjects: 66
Study: 8659482

Group type: EXPERIMENTAL
Intervention: Low animal protein, high fiber diet (56-64 g daily protein, 75 mg daily purine, one-fourth cup of wheat bran, fruits and vegetables) with instructions to drink six to eight glasses of liquid daily and maintain adequate calcium intake.
Number of subjects: 99

Group type: COMPARATOR
Intervention: Control group received advice only on fluid intake and adequate calcium intake.
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Both groups received a mean of 3.4 person-years of follow-up.
Number of subjects: 99
Study: 1825568

Group type: EXPERIMENTAL
Intervention: GR32191 (80 mg po and 40 mg po)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 6833519

Group type: EXPERIMENTAL
Intervention: Desipramine
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Desipramine and Amitriptyline
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: High pretreatment MHPG excretion
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: MHPG excretion
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Gas chromatography method vs gas chromatography/mass spectrometry
Number of subjects: 49
Study: 30770307

Group type: EXPERIMENTAL
Intervention: Oral pioglitazone (45 mg per day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard induction chemotherapy (cytarabine 100 mg/m2 per day for 7 days and daunorubicin 60 mg/m2 per day for 3 days)
Number of subjects: 40
Study: 29199012

Group type: EXPERIMENTAL
Intervention: Suprachoroidal injection of CLS‐TA with intravitreal injection of aflibercept (combination arm)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Only intravitreal injection of aflibercept (monotherapy arm)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Suprachoroidal injection of CLS‐TA
Number of subjects: 38
Study: 26896291

Group type: EXPERIMENTAL
Intervention: Lactobacillus casei strain Shirota (LcS) fermented milk
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lactobacillus casei strain Shirota (LcS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 25244776

Group type: EXPERIMENTAL
Intervention: Yupingfeng droppill and cetirizine tablets
Number of subjects: 76

Group type: COMPARATOR
Intervention: Cetirizine tablets
Number of subjects: 76
Study: 21877203

Group type: EXPERIMENTAL
Intervention: Tenofovir 1% gel (CT cohort)
Number of subjects: 200

Group type: COMPARATOR
Intervention: NCT cohort (control)
Number of subjects: 200
Study: 19761998

Group type: EXPERIMENTAL
Intervention: Antibiotic therapy
Number of subjects: 562

Group type: COMPARATOR
Intervention: Body mass index (BMI)
Number of subjects: 562
Study: 17617809

Group type: EXPERIMENTAL
Intervention: Home dampness
Number of subjects: 6794

Group type: EXPERIMENTAL
Intervention: Visible presence of mold
Number of subjects: 6794
Study: 14687747

Group type: EXPERIMENTAL
Intervention: Photographic reinforcement during postoperative counselling
Number of subjects: 233

Group type: COMPARATOR
Intervention: Control group (no photographic reinforcement)
Number of subjects: 233
Study: 12209372

Group type: EXPERIMENTAL
Intervention: Probiotic yoghurt (yoghurt enriched with L. acidophilus 145, B. longum 913 and 1% oligofructose)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control yoghurt (yoghurt without probiotics)
Number of subjects: 29
Study: 9827838

Group type: EXPERIMENTAL
Intervention: Telephone call 1 week after the emergency department visit
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Telephone call 2 weeks after the visit
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Telephone call 4 weeks after the visit
Number of subjects: 0
Study: 10023014

Group type: EXPERIMENTAL
Intervention: subcutaneous epoetin á 150 U/kg three times a week for up to 12 consecutive weeks (Group A)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: subcutaneous epoetin á 50 U/kg daily for up to 12 consecutive weeks (Group B)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Both groups (A and B)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Group A
Number of subjects: 20
Study: 2676173

Group type: EXPERIMENTAL
Intervention: Sustained release isosorbide-5-mononitrate (ISM) 60 mg
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 9
Study: 343273

Group type: EXPERIMENTAL
Intervention: Propranolol 80 mg twice a day
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg twice a day
Number of subjects: 15
Study: 31065919

Group type: EXPERIMENTAL
Intervention: Standard gastric bypass
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Distal gastric bypass
Number of subjects: 113
Study: 27941058

Group type: EXPERIMENTAL
Intervention: Intravenous exenatide
Number of subjects: 9
Study: 25407260

Group type: EXPERIMENTAL
Intervention: Nifedipine slow-release tablets 20 mg 4 times daily
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 23062214

Group type: EXPERIMENTAL
Intervention: Prednisolone plus Azathioprine
Number of subjects: 56

Group type: COMPARATOR
Intervention: Prednisolone plus placebo
Number of subjects: 56
Study: 20938351

Group type: EXPERIMENTAL
Intervention: 40 Hz ultrabrief-pulse ECT
Number of subjects: 40

Group type: COMPARATOR
Intervention: 100 Hz ultrabrief-pulse ECT
Number of subjects: 40
Study: 19403992

Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (EPA) 1,800 mg daily
Number of subjects: 126
Study: 16362479

Group type: EXPERIMENTAL
Intervention: Laparoscopic gastrojejunostomy (LGJ)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Duodenal stenting (DS)
Number of subjects: 27
Study: 15213620

Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF) administered from 2 days before until day 7 after esophagectomy, standard doses
Number of subjects: 155

Group type: COMPARATOR
Intervention: Placebo administered from 2 days before until day 7 after esophagectomy
Number of subjects: 155
Study: 11304934

Group type: EXPERIMENTAL
Intervention: Doxepin-ratiopharm 25 mg film-coated tablets (test preparation)
Number of subjects: 30

Group type: COMPARATOR
Intervention: 25 mg dragées of the reference preparation (control)
Number of subjects: 30
Study: 9519098

Group type: EXPERIMENTAL
Intervention: Amisulpride
Number of subjects: 60

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 60
Study: 7684422

Group type: EXPERIMENTAL
Intervention: SDZCHH380
Number of subjects: 20

Group type: COMPARATOR
Intervention: OKT3
Number of subjects: 20
Study: 3552464

Group type: EXPERIMENTAL
Intervention: 10 mg nifedipine
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 20 mg nifedipine
Number of subjects: 15

Group type: COMPARATOR
Intervention: 2.5 mg albuterol (Salbutamol)
Number of subjects: 15
Study: 29346473

Group type: EXPERIMENTAL
Intervention: Treatment in primary care
Number of subjects: 288

Group type: COMPARATOR
Intervention: Specialist care
Number of subjects: 288
Study: 27286829

Group type: EXPERIMENTAL
Intervention: Physiotherapist-led triage
Number of subjects: 163

Group type: COMPARATOR
Intervention: Standard practice
Number of subjects: 163
Study: 24116853

Group type: EXPERIMENTAL
Intervention: Adjunctive brivaracetam (BRV) 20-150 mg/day
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Adjunctive brivaracetam (BRV)
Number of subjects: 480

Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 480
Study: 22424659

Group type: EXPERIMENTAL
Intervention: SMART Dai trained TBAs
Number of subjects: 545

Group type: COMPARATOR
Intervention: Untrained TBAs
Number of subjects: 545
Study: 19880139

Group type: EXPERIMENTAL
Intervention: Infant Behavioral Assessment and Intervention Program (IBAIP)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Regular care (Control)
Number of subjects: 86
Study: 18587525

Group type: EXPERIMENTAL
Intervention: Cu-(II)-orotate-dihydrate; 8 mg Cu daily
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study: 15863433

Group type: EXPERIMENTAL
Intervention: Provider tobacco prevention advice
Number of subjects: 4026

Group type: COMPARATOR
Intervention: Tobacco prevention messages from school
Number of subjects: 4026

Group type: COMPARATOR
Intervention: Tobacco prevention messages from parents
Number of subjects: 4026

Group type: COMPARATOR
Intervention: Tobacco prevention messages from mass media
Number of subjects: 4026
Study: 11874243

Group type: EXPERIMENTAL
Intervention: Nasal SCT (200 IU daily)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 10403877

Group type: EXPERIMENTAL
Intervention: EMLA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ametop
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8868206

Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg bid, p.o.)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 2346342

Group type: EXPERIMENTAL
Intervention: Endotracheal administration of atropine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Intravenous administration of atropine
Number of subjects: 20
Study: 4607227

Group type: EXPERIMENTAL
Intervention: Intranasal immunization with inactivated influenza virus vaccine (monovalent or bivalent)
Number of subjects: 10000

Group type: COMPARATOR
Intervention: Intranasal immunization with inactivated influenza virus vaccine (placebo)
Number of subjects: 10000
Study: 31951747

Group type: EXPERIMENTAL
Intervention: HG alert tool in electronic health record system
Number of subjects: 3350

Group type: COMPARATOR
Intervention: Control group (no alerts shown)
Number of subjects: 3350
Study: 30142373

Group type: EXPERIMENTAL
Intervention: Drusenoid pigment epithelial detachment (DPED)
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: ARMS2 risk alleles
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: Increasing genetic risk score (GRS) group
Number of subjects: 325
Study: 28525555

Group type: EXPERIMENTAL
Intervention: Baclofen 180 mg/day
Number of subjects: 320

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 320
Study: 26437720

Group type: EXPERIMENTAL
Intervention: After-school dance intervention (up to 40 sessions of 75 minutes each over 20 weeks)
Number of subjects: 571
Study: 24621799

Group type: EXPERIMENTAL
Intervention: Adaptive servo-ventilation (ASV) mode
Number of subjects: 23

Group type: COMPARATOR
Intervention: Continuous positive airway pressure (CPAP) mode
Number of subjects: 23
Study: 21697706

Group type: EXPERIMENTAL
Intervention: Tailored intervention delivered via Web site and handheld computer
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Handheld computer usage
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Knowledge scores
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Self-efficacy scores
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Web site use
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Handheld computer usage frequency
Number of subjects: 74
Study: 19252346

Group type: EXPERIMENTAL
Intervention: Pioglitazone (45 mg/day) + Sibutramine (10 mg/day)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Metformin (3,000 mg/day) + Sibutramine (10 mg/day)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 105
Study: 16298763

Group type: EXPERIMENTAL
Intervention: Enzogenol (480 mg) and vitamin C (60 mg)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Vitamin C (60 mg) alone
Number of subjects: 44
Study: 14768237

Group type: EXPERIMENTAL
Intervention: Vicryl Rapide
Number of subjects: 120

Group type: COMPARATOR
Intervention: Safil Quick
Number of subjects: 120
Study: 11506097

Group type: EXPERIMENTAL
Intervention: lorazepam
Number of subjects: 24

Group type: COMPARATOR
Intervention: midazolam
Number of subjects: 24
Study: 9230823

Group type: EXPERIMENTAL
Intervention: Brimonidine 0.2% twice daily
Number of subjects: 374

Group type: COMPARATOR
Intervention: Timolol 0.5% twice daily
Number of subjects: 374
Study: 8431330

Group type: EXPERIMENTAL
Intervention: Halothane (end‐tidal)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Isoflurane (end‐tidal)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Nitrous oxide in oxygen
Number of subjects: 38

Group type: COMPARATOR
Intervention: Midazolam 3-10 mg
Number of subjects: 38

Group type: COMPARATOR
Intervention: i.v. technique
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Gender (female)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Anaesthetic technique
Number of subjects: 38
Study: 3583405

Group type: EXPERIMENTAL
Intervention: Desipramine (specific inhibitor of neuronal uptake)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Norepinephrine infusion (1.18 pmol/kg/min) with desipramine
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Hydrocortisone (various doses) during desipramine inhibition
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Hydrocortisone (highest dose without neuronal uptake inhibition)
Number of subjects: 11
Study: 28709817

Group type: EXPERIMENTAL
Intervention: First line treatment with daily oral antihistamine
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Second line treatment with higher dose antihistamine
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Third line treatment with omalizumab or cyclosporine
Number of subjects: 150

Group type: COMPARATOR
Intervention: First line treatment
Number of subjects: 150
Study: 28777519

Group type: EXPERIMENTAL
Intervention: Surgical intervention with HBO₂ therapy (Group 2)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Surgical intervention without HBO₂ therapy (Group 1)
Number of subjects: 22
Study: 26581687

Group type: EXPERIMENTAL
Intervention: 12 week 'self‐selected' supervised exercise training programme with dietary advice
Number of subjects: 360

Group type: COMPARATOR
Intervention: General information on lifestyle and diabetes risk
Number of subjects: 360
Study: 23682517

Group type: EXPERIMENTAL
Intervention: N-butyl-2-cyanoacrylate (Histoacryl)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Staple fixation
Number of subjects: 60
Study: 20528605

Group type: EXPERIMENTAL
Intervention: Asthma communication education intervention (ACE)
Number of subjects: 231

Group type: COMPARATOR
Intervention: Asthma education control group (CON)
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Both groups (ACE and CON)
Number of subjects: 231
Study: 19139247

Group type: EXPERIMENTAL
Intervention: Enhanced caregiver support intervention
Number of subjects: 254

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 254
Study: 16689065

Group type: COMPARATOR
Intervention: No liner or base
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Liner only
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Base only
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Base and liner
Number of subjects: 40
Study: 15305893

Group type: EXPERIMENTAL
Intervention: Meningococcal septicaemia
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Meningococcal septicaemia with pulmonary oedema
Number of subjects: 24

Group type: COMPARATOR
Intervention: Controls with noninfectious critical illness
Number of subjects: 24
Study: 11587207

Group type: EXPERIMENTAL
Intervention: CMC3 regimen (2‐CdA 0.12 mg/kg for 3 days, mitoxantrone 10 mg/m2 on day 1, cyclophosphamide 650 mg/m2 on day 1)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: CMC5 regimen (2‐CdA 0.12 mg/kg for 5 days, mitoxantrone 10 mg/m2 on day 1, cyclophosphamide 650 mg/m2 on day 1)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: CMC5 regimen
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: CMC3 regimen
Number of subjects: 62
Study: 9436689

Group type: EXPERIMENTAL
Intervention: Long GnRH‐a
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Short GnRH‐a
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: No GnRH‐a
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Pregnant women (after embryo transfer)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Non-pregnant patients
Number of subjects: 60
Study: 8011571

Group type: EXPERIMENTAL
Intervention: Anipamil 80 mg once daily
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Anipamil 160 mg once daily
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 2442550

Group type: EXPERIMENTAL
Intervention: Lisinopril (LIS) 20, 40, and 80 mg
Number of subjects: 394

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ) 12.5, 25, and 50 mg
Number of subjects: 394

Group type: EXPERIMENTAL
Intervention: Lisinopril + Hydrochlorothiazide (LIS + HCTZ) 20 + 12.5, 40 + 25, and 80 + 50 mg
Number of subjects: 394
Study: 31822399

Group type: EXPERIMENTAL
Intervention: Selinexor (35 or 50 mg/m2 twice‐weekly [BIW] or 50 mg/m2 once‐weekly [QW])
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Selinexor (50 mg/m2 QW)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Selinexor
Number of subjects: 114
Study: 30768411

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) for anxiety
Number of subjects: 80

Group type: COMPARATOR
Intervention: Child-centered therapy (CCT)
Number of subjects: 80
Study: 28238674

Group type: EXPERIMENTAL
Intervention: Participatory Action Research (PAR) weekly sessions
Number of subjects: 30

Group type: COMPARATOR
Intervention: Active control (weekly reminiscence activity)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Passive control (care as usual)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Qualitative experience of PAR participants
Number of subjects: 30
Study: 25928739

Group type: EXPERIMENTAL
Intervention: Intervention 1 (attendance incentives)
Number of subjects: 1300

Group type: EXPERIMENTAL
Intervention: Intervention 2 (attendance incentives and tailored support)
Number of subjects: 1300

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1300
Study: 23615633

Group type: EXPERIMENTAL
Intervention: Combination treatment with telmisartan (80 mg/d) and aliskiren (300 mg/d)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Combination treatment with telmisartan (160 mg/d) alone
Number of subjects: 18

Group type: COMPARATOR
Intervention: Combination treatment with telmisartan (80 mg/d) and eplerenone (50 mg/d)
Number of subjects: 18
Study: 21840177

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (twice daily for 14 days)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (twice daily for 14 days)
Number of subjects: 20
Study: 19377488

Group type: EXPERIMENTAL
Intervention: 10 mg tadalafil
Number of subjects: 1046

Group type: EXPERIMENTAL
Intervention: 20 mg tadalafil
Number of subjects: 1046

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1046
Study: 17125930

Group type: EXPERIMENTAL
Intervention: l-Arg (400 mg/kg/day)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: l-Arg (200 mg/kg/day)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control (no l-Arg supplementation)
Number of subjects: 47
Study: 15352969

Group type: EXPERIMENTAL
Intervention: Intravenous parecoxib 40 mg followed by oral valdecoxib 40 mg qd
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11435054

Group type: EXPERIMENTAL
Intervention: Mivacurium 0.03 mg/kg
Number of subjects: 45

Group type: COMPARATOR
Intervention: Normal saline 0.5 mL
Number of subjects: 45

Group type: COMPARATOR
Intervention: Gallamine 0.04 mg/kg
Number of subjects: 45
Study: 9764260

Group type: EXPERIMENTAL
Intervention: Midwife home visiting programme (Group A)
Number of subjects: 408

Group type: COMPARATOR
Intervention: Control group (Group B)
Number of subjects: 408
Study: 7878625

Group type: EXPERIMENTAL
Intervention: Hirulog 1.0 mg/kg subcutaneously
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Hirulog 0.6 mg/kg as a 15 min intravenous infusion
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Hirulog (both regimens)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (conventional anticoagulants)
Number of subjects: 10
Study: 3067338

Group type: EXPERIMENTAL
Intervention: Olsalazine, 2 g/day
Number of subjects: 126

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study: 29067495

Group type: EXPERIMENTAL
Intervention: Tocilizumab (TCZ) 162 mg subcutaneously
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Tocilizumab (TCZ)
Number of subjects: 28
Study: 26541724

Group type: EXPERIMENTAL
Intervention: Laparoscopic Sleeve Gastrectomy (LSG)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Laparoscopic Greater Curvature Plication (LGCP)
Number of subjects: 54
Study: 24964511

Group type: EXPERIMENTAL
Intervention: Saunders lumbar traction
Number of subjects: 140

Group type: COMPARATOR
Intervention: Pharmacological treatment
Number of subjects: 140
Study: 22949743

Group type: EXPERIMENTAL
Intervention: Promoting First Relationships (PFR) intervention for caregivers
Number of subjects: 210

Group type: COMPARATOR
Intervention: Comparison condition
Number of subjects: 210